ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VENN Venn Life Sciences Holdings Plc

6.85
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Venn Life Sciences Holdings Plc LSE:VENN London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.85 6.70 7.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

AIM Schedule One - Open Orphan plc (7518Y)

06/01/2020 8:00am

UK Regulatory


TIDMORPH

RNS Number : 7518Y

AIM

06 January 2020

 
        ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION 
         IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM 
                                    RULES") 
 
 COMPANY NAME: 
 Open Orphan plc 
 COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY 
  TRADING ADDRESS (INCLUDING POSTCODES) : 
 Registered Office: 
 
  PO Box W1J 6BD, Berkley Square House, 2nd Floor, Mayfair, London, 
  W1J 8DJ 
 
  Trading Offices: 
 
  19 Railway Road, Dalkey, Dublin, Ireland 
  Queen Mary BioEnterprises (QMB) Innovation Centre, 42 New Road, 
  London, E1 2AX 
 COUNTRY OF INCORPORATION: 
 England and Wales 
 COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED 
  BY AIM RULE 26: 
 www.openorphan.com 
 COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, 
  IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING 
  POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE 
  TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: 
 This is a reverse takeover under Rule 14. 
 
  Open Orphan is a Clinical Research Organisation that specialises 
  in rare and orphan drugs. The headquarters are in Dublin, Ireland 
  and the company also has offices in the UK, France, the Netherlands 
  and Germany. 
 DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS 
  AS TO TRANSFER OF THE SECURITIES (i.e. where known, number 
  and type of shares, nominal value and issue price to which 
  it seeks admission and the number and type to be held as treasury 
  shares): 
 Number of ordinary shares of 0.1 pence each in nominal value 
  ("Ordinary Shares") for which Admission will be sought: TBC 
 
  There are no restrictions as to the transferability of the 
  Ordinary Shares and no Ordinary Shares will be held in treasury. 
 CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) 
  AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: 
 Expected Market Capitalisation: TBC 
 PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: 
 TBC 
 DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH 
  THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE 
  OR WILL BE ADMITTED OR TRADED: 
 Euronext Growth 
 FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS 
  (underlining the first name by which each is known or including 
  any other name by which each is known): 
 Directors 
  Cathal Friel, Executive Chairman 
  Brendan Buckley, Non-executive Director 
 
  Proposed Directors 
  Dr Trevor Phillips, Chief Executive Officer 
  Dr Mark Warne, Non-executive Director 
  Michael Meade, Non-executive Director 
 FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED 
  AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER 
  ADMISSION (underlining the first name by which each is known 
  or including any other name by which each is known): 
 Before Admission: 
   Name                              Number of Ordinary   Percentage of issued 
                                                 Shares          share capital 
   Cathal Friel                              41,046,981                  16.1% 
                                    -------------------  --------------------- 
   Anthony (Tony) Richardson                 16,313,388                   6.4% 
                                    -------------------  --------------------- 
   Gresham House Asset Management            13,081,337                   5.1% 
                                    -------------------  --------------------- 
   Crux Asset Management                     11,928,571                   4.7% 
                                    -------------------  --------------------- 
   Brendan Buckley                            7,845,860                   3.1% 
                                    -------------------  --------------------- 
 
 
 
  After Admission: 
   Name                             Number of Ordinary   Percentage of issued 
                                                Shares          share capital 
   Cathal Friel                             41,046,981                    TBC 
                                   -------------------  --------------------- 
   Anthony (Tony) Richardson                16,313,388                    TBC 
                                   -------------------  --------------------- 
   Gresham House Asset Management           13,081,337                    TBC 
                                   -------------------  --------------------- 
   Crux Asset Management                    11,928,571                    TBC 
                                   -------------------  --------------------- 
   Brendan Buckley                           7,845,860                    TBC 
                                   -------------------  --------------------- 
   Invesco Ltd                              52,485,973                    TBC 
                                   -------------------  --------------------- 
   Link Fund Solutions Ltd                  38,618,608                    TBC 
                                   -------------------  --------------------- 
   IP Group plc                             32,267,791                    TBC 
                                   -------------------  --------------------- 
   Jupiter Asset Management                 22,819,579                    TBC 
    Ltd 
                                   -------------------  --------------------- 
 NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 
  2, PARAGRAPH (H) OF THE AIM RULES: 
 n/a 
 (i) ANTICIPATED ACCOUNTING REFERENCE DATE 
  (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION 
  DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited 
  interim financial information) 
  (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS 
  PURSUANT TO AIM RULES 18 AND 19: 
      (i) 31 December 
       (ii) 31 December 2019 
       (iii) 31 December 2019 due 30 June 2020, 30 June 2020 due September 
       2020, 31 December 2020 due 30 June 2021 
 EXPECTED ADMISSION DATE: 
 20 January 2020 
 NAME AND ADDRESS OF NOMINATED ADVISER: 
 Arden Partners plc 
  125 Old Broad Street 
  London 
  EC2N 1AR 
 NAME AND ADDRESS OF BROKER: 
 Arden Partners plc 
  125 Old Broad Street 
  London 
  EC2N 1AR 
 OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE 
  (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE 
  AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL 
  DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: 
 A copy of the admission document containing full details about 
  the applicant and the admission of its securities is available 
  on the Company's website, www.openorphan.com 
 THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO 
  APPLY 
 The QCA Corporate Governance Code 2018 published by the Quoted 
  Companies Alliance 
 DATE OF NOTIFICATION: 
 6 January 2020 
 NEW/ UPDATE: 
 NEW 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

PAASSSFMDESSEDF

(END) Dow Jones Newswires

January 06, 2020 03:00 ET (08:00 GMT)

1 Year Venn Life Sciences Chart

1 Year Venn Life Sciences Chart

1 Month Venn Life Sciences Chart

1 Month Venn Life Sciences Chart

Your Recent History

Delayed Upgrade Clock